The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
Marguerite Vasseur
Page 2 of 10 of this archive, newest first.
Archive — page 2
182 piecesSTEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The same signature, the same peak, three different batches
A blank certificate with the numbers left editable is an ordinary internal document. Its circulation as a finished record is the problem.
Reading the mazdutide titration schedule as a regulatory artefact
What the regulatory dossiers actually contain on dose selection is remarkably thin, and worth knowing before treating the ladder as settled science.
STEP 8 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the trial protocols permitted, and what the labels omitted
Nausea and gastric delay attenuate over weeks at an unchanged dose. That single physiological fact is the entire justification for holding.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Vitamin D, adiposity, and a volume-of-distribution problem
What the trials measured, which in the case of micronutrients is very little.
Reading the receptor: what distinguishes survodutide from liraglutide at the molecular level
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Beta-arrestin, cAMP, and the part of dulaglutide’s mechanism nobody quotes
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
An error taxonomy for a market without a pharmacist
The recurring errors in this market are not exotic. They are a small set of arithmetic and reading failures, each capable of moving a dose by a factor of two or ten.
What a low result means when intake has halved
What the trials measured, which in the case of micronutrients is very little.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holding a dose is a decision, not a failure
A dose held long enough stops being a pause and becomes a maintenance decision. That transition is rarely made explicitly.
The escalation table is the thinnest page in the label
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Storage after reconstitution, and the evidence behind the numbers
The air shot before a pen injection removes air from the cartridge and confirms flow. Skipping it can mean a materially reduced dose, and it is skipped constantly.